EP2646055A4 - In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents - Google Patents
In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agentsInfo
- Publication number
- EP2646055A4 EP2646055A4 EP11846041.9A EP11846041A EP2646055A4 EP 2646055 A4 EP2646055 A4 EP 2646055A4 EP 11846041 A EP11846041 A EP 11846041A EP 2646055 A4 EP2646055 A4 EP 2646055A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- therapeutic
- delivery
- diagnostic agents
- click chemistry
- free click
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Radiology & Medical Imaging (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41908210P | 2010-12-02 | 2010-12-02 | |
US12/958,889 US8202509B2 (en) | 2007-01-11 | 2010-12-02 | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
PCT/US2011/063006 WO2012075361A2 (en) | 2010-12-02 | 2011-12-02 | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2646055A2 EP2646055A2 (en) | 2013-10-09 |
EP2646055A4 true EP2646055A4 (en) | 2015-04-08 |
Family
ID=46172588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11846041.9A Withdrawn EP2646055A4 (en) | 2010-12-02 | 2011-12-02 | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2646055A4 (en) |
CN (1) | CN103221072A (en) |
AU (1) | AU2011336396B2 (en) |
CA (1) | CA2814962A1 (en) |
WO (1) | WO2012075361A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101416290B1 (en) * | 2012-03-20 | 2014-07-09 | 한국과학기술연구원 | Method for in vivo targeting of nanoparticles via bioorthogonal copper-free click chemistry |
WO2014138186A1 (en) * | 2013-03-05 | 2014-09-12 | The Johns Hopkins University | Bioorthogonal two-component delivery systems for enhanced internalization of nanotherapeutics |
DK2991683T3 (en) | 2013-05-02 | 2019-11-04 | Glykos Finland Oy | CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC CHARGE |
CN103951668A (en) * | 2014-04-25 | 2014-07-30 | ***广州总医院 | Positron isotope label of folic acid ramification and application thereof |
CN104529898B (en) * | 2015-01-15 | 2016-07-27 | 成都丽凯手性技术有限公司 | Azepine dibenzo cyclooctyne compounds and preparation method thereof |
CN108289932A (en) * | 2015-05-22 | 2018-07-17 | D·D·格恩金 | Extracellular dna is as neurodegenerative therapy target |
US20170007727A1 (en) * | 2015-07-07 | 2017-01-12 | Immunomedics, Inc. | METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES |
SG10202007520WA (en) | 2016-03-02 | 2020-09-29 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
WO2019125982A1 (en) * | 2017-12-18 | 2019-06-27 | Janssen Biotech, Inc. | Radiolabeling of polypeptides |
CN109675052B (en) * | 2019-01-29 | 2022-02-15 | 中国药科大学 | Efficient targeting conjugate triggered by biological click, and multi-component composition, preparation method and application thereof |
CN112457401B (en) * | 2020-10-21 | 2023-02-24 | 上海交通大学医学院附属仁济医院 | Molecular imaging probe for diagnosing multiple myeloma |
CN113372413B (en) * | 2021-05-17 | 2022-09-27 | 复旦大学附属中山医院 | PET (polyethylene terephthalate) imaging agent targeting CD11b receptor, labeled precursor thereof, preparation method, composition and application thereof |
CN113476619B (en) * | 2021-07-08 | 2022-11-29 | 上海交通大学医学院附属仁济医院 | A kind of 18 F-labeled nano antibody probe and preparation method and application thereof |
CN115282299B (en) * | 2022-07-20 | 2024-01-12 | 北京大学深圳研究生院 | TGF beta tracer, antibody probe preparation method and application |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009135015A2 (en) * | 2008-04-30 | 2009-11-05 | Immunomedics, Inc. | Improved methods and compositions for f-18 labeling of proteins, peptides and other molecules |
WO2010017500A2 (en) * | 2008-08-08 | 2010-02-11 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8153100B2 (en) * | 2007-01-11 | 2012-04-10 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
US8685937B2 (en) * | 2008-08-09 | 2014-04-01 | University Of Iowa Research Foundation | Nucleic acid aptamers |
EP3470087A1 (en) * | 2009-02-13 | 2019-04-17 | Immunomedics, Inc. | Lyophilised compositions of immunoconjugates with an intracellularly-cleavable linkage |
-
2011
- 2011-12-02 CN CN2011800548970A patent/CN103221072A/en active Pending
- 2011-12-02 WO PCT/US2011/063006 patent/WO2012075361A2/en active Application Filing
- 2011-12-02 AU AU2011336396A patent/AU2011336396B2/en active Active
- 2011-12-02 CA CA2814962A patent/CA2814962A1/en active Pending
- 2011-12-02 EP EP11846041.9A patent/EP2646055A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009135015A2 (en) * | 2008-04-30 | 2009-11-05 | Immunomedics, Inc. | Improved methods and compositions for f-18 labeling of proteins, peptides and other molecules |
WO2010017500A2 (en) * | 2008-08-08 | 2010-02-11 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
Non-Patent Citations (1)
Title |
---|
MARIK J ET AL: "Click for PET: rapid preparation of [<18>F]fluoropeptides using Cu<I> catalyzed 1,3-dipolar cycloaddition", TETRAHEDRON LETTERS, PERGAMON, GB, vol. 47, no. 37, 11 September 2006 (2006-09-11), pages 6681 - 6684, XP025004843, ISSN: 0040-4039, [retrieved on 20060911], DOI: 10.1016/J.TETLET.2006.06.176 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012075361A3 (en) | 2012-07-26 |
AU2011336396B2 (en) | 2016-02-04 |
EP2646055A2 (en) | 2013-10-09 |
CN103221072A (en) | 2013-07-24 |
AU2011336396A1 (en) | 2013-04-18 |
WO2012075361A2 (en) | 2012-06-07 |
CA2814962A1 (en) | 2012-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2646055A4 (en) | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents | |
IL276643A (en) | Methods of enhancing drug delivery and effectiveness of therapeutic agents | |
IL239557A0 (en) | Microarray for delivery of therapeutic agent and methods of use | |
EP2445568A4 (en) | Steerable medical delivery devices and methods of use | |
HK1176895A1 (en) | Therapeutic agent delivery system and method for localized application of therapeutic substances to a biological lumen | |
EP2413917A4 (en) | Drug delivery system and methods of use | |
IL226127A0 (en) | Composition comprising proteins and oligosaccharides for treating skin diseases | |
EP2635185A4 (en) | Determination of tissue oxygenation in vivo | |
IL213410A0 (en) | Methods and compositions for diagnostic use in cancer patients | |
EP2403447A4 (en) | Microencapsulated bioactive agents for oral delivery and methods of use thereof | |
IL214255A0 (en) | Methods and compositions for diagnosis and treatment of cancer | |
HK1243436A1 (en) | Therapeutic use of specific ligand in msrv associated diseases | |
IL236516A0 (en) | Methods and compositions for diagnosis and treatment of cancer | |
EP2606349A4 (en) | Cancer diagnostic and cancer therapeutic | |
EP2563426A4 (en) | High shear application in medical therapy | |
GB201108964D0 (en) | Medicament and method of diagnosis | |
IL203130A (en) | Cd44 splice variants for use in diagnosis and treatment of neurodegenerative diseases | |
GB0918392D0 (en) | Diagnostic and therapeutic methods | |
GB0920258D0 (en) | New medical agents and use thereof | |
HK1168283A1 (en) | Sorcs1-like agent for use in the treatment of insulin resistance and diseases related thereto sorcs1 | |
EP2470268A4 (en) | Purine-targeted diagnosis and therapy of wounds | |
EP2438167A4 (en) | Therapeutic and diagnostic molecules | |
EP2525823A4 (en) | Delivery system for diagnostic and therapeutic agents | |
EP2384370A4 (en) | Use of id4 for diagnosis and treatment of cancer | |
EP2556379A4 (en) | New diagnostic and therapeutic target |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130701 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150305 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/395 20060101AFI20150227BHEP |
|
17Q | First examination report despatched |
Effective date: 20170929 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20181127 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190409 |